The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Neoadjuvant bevacizumab with weekly nab-paclitaxel plus carboplatin followed by doxorubicin plus cyclophosphamide (AC) for triple-negative breast cancer.
Jessica N. Snider
No relevant relationships to disclose
Robyn R. Young
Honoraria - Celgene
Lee Steven Schwartzberg
No relevant relationships to disclose
Jeffrey Warren Allen
No relevant relationships to disclose
Yasir Ahmed Javed
No relevant relationships to disclose
Mohammad Jahanzeb
No relevant relationships to disclose
Jasgit C. Sachdev
Research Funding - Celgene; Roche